Join to view full profile
810 Jasonway AveSte AColumbus, OH 43214
Phone+1 614-442-3130
Fax+1 614-442-3145
Dr. Macrae is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Erin Macrae is a board-certified Medical Oncologist, a Partner at Columbus Oncology and Hematology Associates, and the Medical Director of OncoveryCare. With over 20 years of experience, she has extensive expertise in clinical oncology leadership and the clinical management of solid tumors, specifically gastrointestinal (GI) tumors and breast cancer. Formerly a faculty member in the Division of Medical Oncology at The Ohio State University, Dr. Macrae is deeply committed to advancing oncology care delivery, practice management, clinical research and survivorship care.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2008 - 2011
University of Pennsylvania Health SystemResidency, Internal Medicine, 2005 - 2008
Case Western Reserve University School of MedicineClass of 2005
Certifications & Licensure
GA State Medical License 2026 - 2028
NY State Medical License 2026 - 2028
OH State Medical License 2011 - 2028
TN State Medical License 2026 - 2027
PA State Medical License 2005 - 2008
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification iKnowMed EHR, McKesson, 2012, 2014, 2016-2017
Clinical Trials
- T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
- Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer Start of enrollment: 2013 Oct 02
- Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H) Start of enrollment: 2016 Jan 04
Publications & Presentations
PubMed
- Phase II Study of Dabrafenib and Trametinib in Patients With Tumors WithMutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol H.April K S Salama, Victoria Wang, Erin R Macrae, Jong-In Park, Helen X Chen
JCO Precision Oncology. 2026-01-01 - 8 citationsPhase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer.Vishnu Prasath, Hinda Boutrid, Robert Wesolowski, Mahmoud Abdel-Rasoul, Cynthia Timmers
Breast Cancer Research and Treatment. 2025-02-01 - 4 citationsAn Open-Label Study of Subcutaneous CpG Oligodeoxynucleotide (PF03512676) in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer.Dionisia Quiroga, Robert Wesolowski, Sara Zelinskas, Ashley Pinette, Brooke Benner
Cancer Control. 2024-05-27
Press Mentions
Examples Help Breast Cancer Patients UnderstandMarch 31st, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
